Cotargeting EGFR and autophagy signaling: A novel therapeutic strategy for non-small-cell lung cancer

Abstract excerpt

epidermal growth factor receptor (EGFR) somatic mutations are found in the majority of non‑small‑cell lung cancers (NSCLCs) and patients with NSCLC who harbor EGFR mutations have been shown to exhibit increased sensitivity to the small‑molecule EGFR‑tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. However, the majority of tumors develop acquired resistance to EGFR‑TKIs after a median of 10‑16 months,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Autophagy in Disease and Therapy
• Share to Cancer-related gene regulation
• Share to Lung Cancer Treatments and Mutations